Skip to main content
SpringerLink
Log in

Combination of Bevacizumab and NGF Reduces the Risk of Diabetic Retinopathy

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Accumulated evidences support diabetic retinopathy is caused by functional and structural alterations in both the microvascular and neuroglial compartments. Here, we explored any beneficial effects of combination of Bevacizumab and NGF to prevent diabetic retinopathy. STZ-induced diabetic rats were randomly grouped into three groups: sham, Bevacizumab and combination group (Bevacizumab + NGF). End of the treatment, vascular abnormality was evaluated by FITC-dextran. Inflammation and angiogenesis factors were also investigated by real-time PCR and western blot. Our results showed both Bevacizumab and the combination could dramatically reduce abnormal vascular permeability and limit the inflammatory and angiogenesis in 6-week diabetic rats. However, the combination indicated better preventive effects in 12-week diabetic rats compared with Bevacizumab alone. Our findings suggest that the combination of Bevacizumab with NGF may be a new method for the preventive intervention of diabetic retinopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Pascolini, D., & Mariotti, S. P. (2012). Global estimates of visual impairment: 2010. British Journal of Ophthalmology, 96, 614–618.

    Article  PubMed  Google Scholar 

  2. Sivaprasad, S., Gupta, B., Crosby-Nwaobi, R., & Evans, J. (2012). Prevalence of diabetic retinopathy in various ethnic groups: A worldwide perspective. Survey of Ophthalmology, 57, 347–370.

    Article  PubMed  Google Scholar 

  3. Yau, J. W., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., et al. (2012). Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 35, 556–564.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Lock, J. H., & Fong, K. C. (2011). An update on retinal laser therapy. Clinical and Experimental Optometry, 94, 43–51.

    Article  PubMed  Google Scholar 

  5. Giuliari, G. P. (2012). Diabetic retinopathy: Current and new treatment options. Current Diabetes Review, 8, 32–41.

    Article  Google Scholar 

  6. Stewart, M. W. (2012). Corticosteroid use for diabetic macular edema: Old fad or new trend? Current Diabetes Reports, 12, 364–375.

    Article  CAS  PubMed  Google Scholar 

  7. Adamis, A. P., Miller, J. W., Bernal, M. T., Folkman, J., Yeo, T. K., et al. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. American Journal of Ophthalmology, 118, 445–450.

    Article  CAS  PubMed  Google Scholar 

  8. Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., et al. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine, 331, 1480–1487.

    Article  CAS  PubMed  Google Scholar 

  9. Zechmeister-Koss, I., & Huic, M. (2012). Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. British Journal of Ophthalmology, 96, 167–178.

    Article  PubMed  Google Scholar 

  10. Barber, A. J., Lieth, E., Khin, S. A., Antonetti, D. A., Buchanan, A. G., & Gardner, T. W. (1998). Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. Journal of Clinical Investigation, 102, 783–791.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Mizutani, M., Gerhardinger, C., & Lorenzi, M. (1998). Muller cell changesin human diabetic retinopathy. Diabetes, 47, 445–449.

    Article  CAS  PubMed  Google Scholar 

  12. Colafrancesco, Valeria, Coassin, Marco, Rossi, Simona, & Aloe, Luigi. (2011). Effect of eye NGF administration on two animal models of retinal ganglion cells degeneration. Annali dell Superiore di Sanità, 47(3), 284–289.

    CAS  Google Scholar 

  13. Colafrancesco, V., Coassin, M., Rossi, S., & Aloe, L. (2011). Effect of eye NGF administration on two animal models of retinal ganglion cells degeneration. Annali dell Istituto Superiore di Sanita, 47(3), 284–289.

    CAS  PubMed  Google Scholar 

  14. Ma, J., Zhu, T., Tang, X., Ye, P., & Zhang, Z. (2010). Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. Clinical and Experimental Ophthalmology, 38(9), 875–884.

    Article  PubMed  Google Scholar 

  15. Yoshimura, T., Sonoda, K. H., Sugahara, M., Mochizuki, Y., Enaida, H., et al. (2009). Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One, 4, e8158.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Elner, S. G., Elner, V. M., Jaffe, G. J., Stuart, A., Kunkel, S. L., et al. (1995). Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Current Eye Research, 14, 1045–1053.

    Article  CAS  PubMed  Google Scholar 

  17. Fonollosa, A., Garcia-Arumi, J., Santos, E., Macia, C., Fernandez, P., et al. (2010). Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion. Eye (Lond), 24, 1284–1290.

    Article  CAS  Google Scholar 

  18. Schoenberger, S. D., Kim, S. J., Sheng, J., Rezaei, K. A., Lalezary, M., et al. (2012). Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Investigative Ophthalmology and Visual Science, 53, 5906–5911.

    Article  CAS  PubMed  Google Scholar 

  19. Wakabayashi, Y., Usui, Y., Okunuki, Y., Kezuka, T., Takeuchi, M., et al. (2010). Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina, 30, 339–344.

    Article  PubMed  Google Scholar 

  20. Watanabe, D., Suzuma, K., Suzuma, I., Ohashi, H., Ojima, T., et al. (2005). Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. American Journal of Ophthalmology, 139, 476–481.

    Article  CAS  PubMed  Google Scholar 

  21. Freyberger, H., Bröcker, M., Yakut, H., Hammer, J., Effert, R., et al. (2000). Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Experimental and Clinical Endocrinology and Diabetes, 108, 106–109.

    Article  CAS  PubMed  Google Scholar 

  22. Butler, J. M., Guthrie, S. M., Koc, M., Afzal, A., Caballero, S., et al. (2005). SDF-1 is both necessary and sufficient to promote proliferative retinopathy. Journal of Clinical Investigation, 115, 86–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Manzano, R. P., Peyman, G. A., Khan, P., et al. (2007). Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). British Journal of Ophthalmology, 91, 804–807.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Klettner, A., & Roider, J. (2008). Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: Efficiency and possible additional pathways. Investigative Ophthalmology and Visual Science, 49, 4523–4527.

    Article  PubMed  Google Scholar 

  25. Ameri, H., Chader, G. J., Kim, J., et al. (2007). The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Investigative Ophthalmology and Visual Science, 48, 5708–5715.

    Article  PubMed  Google Scholar 

  26. Lassota, N., Prause, J. U., Scherfig, E., et al. (2010). Clinical and histological findings after intravitreal injection of bevacizumab (Avastin(R) in a porcine model of choroidal neovascularization. Acta Ophthalmologica, 88, 300–308.

    Article  CAS  PubMed  Google Scholar 

  27. Heiduschka, P., Fietz, H., Hofmeister, S., et al. (2007). Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Investigative Ophthalmology and Visual Science, 48, 2814–2823.

    Article  PubMed  Google Scholar 

  28. Bloodworth, J. M, Jr. (1962). Diabetic retinopathy. Diabetes, 11, 1–22.

    PubMed  Google Scholar 

  29. Wolter, J. R. (1961). Diabetic retinopathy. American Journal of Ophthalmology, 51, 1123–1141.

    CAS  PubMed  Google Scholar 

  30. Hammes, H. P., Federoff, H. J., & Brownlee, M. (1995). Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Molecular Medicine, 1, 527–534.

    PubMed Central  CAS  PubMed  Google Scholar 

  31. Martin, P. M., Roon, P., Van Ells, T. K., Ganapathy, V., & Smith, S. B. (2004). Death of retinal neurons in streptozotocin-induced diabetic mice. Investigative Ophthalmology and Visual Science, 45, 3330–3336.

    Article  PubMed  Google Scholar 

  32. Ali, T. K., Matragoon, S., Pillai, B. A., Liou, G. I., & El-Remessy, A. B. (2008). Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes. Diabetes, 57, 889–898.

    Article  CAS  PubMed  Google Scholar 

  33. El-Remessy, A. B., Khalifa, Y., Ola, S., & Liou, G. (2010). Diabetes-induced tyrosine nitration impairs glutamine synthetase activity: Protective effects of cannabidiol. Molecular Vision, 16, 1487–1495.

    PubMed Central  CAS  PubMed  Google Scholar 

  34. Connor, B., & Dragunow, M. (1998). The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Research, 27, 1–39.

    Article  CAS  PubMed  Google Scholar 

  35. Yune, T. Y., Lee, J. Y., Jung, G. Y., Kim, S. J., Jiang, M. H., Kim, Y. C., et al. (2007). Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. Journal of Neuroscience, 27, 7751–7761.

    Article  CAS  PubMed  Google Scholar 

  36. Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001). Regulation of cell survival by secreted proneurotrophins. Science, 294, 1945–1948.

    Article  CAS  PubMed  Google Scholar 

  37. Von Bartheld, C. S. (1998). Neurotrophins in the developing and regenerating visual system. Histology and Histopathology, 13, 437–459.

    Google Scholar 

  38. Ali, T. K., Al-Gayyar, M. M. H., Matragoon, S., Pillai, B. A., Abdelsaid, M. A., Nussbaum, J. J., & El-Remessy, A. B. (2010). Diabetes-induced peroxynitrite impairs the balance of ProNGF/NGF and causes neurovascular injury. Diabetologia, 54(3), 657–668.

    Article  PubMed  Google Scholar 

  39. Jee, D., & Lee, W. K. (2012). Inhibitory effect of intravitreal injection of bevacizumab on nerve growth factor. Current Eye Research, 37(5), 408–415.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, The Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong, People’s Republic of China

    Peipei Zhang

  2. Qingdao Municipal Hospital, No.1 Jiaozhou Road, Qingdao, Shandong, People’s Republic of China

    Zhanyu Zhou

Authors
  1. Peipei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhanyu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhanyu Zhou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, P., Zhou, Z. Combination of Bevacizumab and NGF Reduces the Risk of Diabetic Retinopathy. Cell Biochem Biophys 73, 79–85 (2015). https://doi.org/10.1007/s12013-015-0564-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-015-0564-1

Keywords

Search

Navigation